Advertisement

Advertisement

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Lung Cancer
Genomics/Genetics

Second-Line Sotorasib Plus Afatinib for KRAS-Mutant NSCLC

The combination of the KRAS inhibitor sotorasib with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating patients with non–small cell lung cancer (NSCLC) and mutated KRAS whose di...

CNS Cancers

DM-CHOC-PEN May Improve Outcomes for Adolescents and Young Adults With Central Nervous System Tumors

In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young adult patients with cancers involving the central n...

Lung Cancer

Can Inhibition of the Aurora Kinase A Protein Help Overcome Resistance to KRAS Inhibition in Patients With Lung Cancer?

In preclinical models, combining an investigational Aurora kinase A (AURKA) inhibitor with a KRAS inhibitor or a WEE1 inhibitor showed efficacy against lung cancer cells with intrinsic or acquired res...

Advertisement

Advertisement



Advertisement